Literature DB >> 18243397

Economic evaluations of dialysis treatment modalities.

Paul Michael Just1, Miguel Carlos Riella, Elizabeth Ann Tschosik, Leslie Lyle Noe, Samir Kumar Bhattacharyya, Frank de Charro.   

Abstract

OBJECTIVES: The purpose of this paper is to review published economic evaluations of dialysis treatment modalities, including hemodialysis (HD) and peritoneal dialysis (PD).
METHODS: A systematic literature review was conducted in both PubMed and EMBASE for the years 1996-2006. Articles were included if they were original research articles comparing PD and HD or comparing subtypes of PD and HD.
RESULTS: Twenty-five articles were included in the formal literature review. The majority of articles were cost evaluations, rather than full economic evaluations of both costs and outcomes. The results show that, in developed nations, HD is generally more expensive than PD to the payer. In developing and emerging economies, mainly due to inexpensive labor and high imported equipment and solution costs, PD is not infrequently perceived to be more expensive than HD. However, the costs of dialysis differ by region and additional research is needed particularly in developing economies.
CONCLUSIONS: HD is a more expensive dialysis modality in developed regions of the world. Research in the developing world is too limited to draw definitive conclusions.

Entities:  

Mesh:

Year:  2008        PMID: 18243397     DOI: 10.1016/j.healthpol.2007.12.004

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  33 in total

1.  Global trends in rates of peritoneal dialysis.

Authors:  Arsh K Jain; Peter Blake; Peter Cordy; Amit X Garg
Journal:  J Am Soc Nephrol       Date:  2012-02-02       Impact factor: 10.121

Review 2.  Renal replacement therapy review: past, present and future.

Authors:  Geoffrey M Fleming
Journal:  Organogenesis       Date:  2011-01-01       Impact factor: 2.500

3.  Healthcare costs of the progression of chronic kidney disease and different dialysis techniques estimated through administrative database analysis.

Authors:  Alessandro Roggeri; Daniela Paola Roggeri; Carlo Zocchetti; Maurizio Bersani; Ferruccio Conte
Journal:  J Nephrol       Date:  2016-05-10       Impact factor: 3.902

4.  Incidence of end-stage renal disease in the elderly: a steadily rising global socioeconomic epidemic.

Authors:  Kosmas I Paraskevas; Nikolaos Bessias; Sotirios A Koupidis; Effie Tziviskou; Dimitri P Mikhailidis; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2009-12-18       Impact factor: 2.370

5.  Dialysis: Choice of dialysis--what to do with economic incentives.

Authors:  Kai Ming Chow; Philip Kam-Tao Li
Journal:  Nat Rev Nephrol       Date:  2012-07-31       Impact factor: 28.314

Review 6.  Peritoneal dialysis and the process of modality selection.

Authors:  Peter G Blake; Robert R Quinn; Matthew J Oliver
Journal:  Perit Dial Int       Date:  2013 May-Jun       Impact factor: 1.756

7.  Spatial Analysis of Case-Mix and Dialysis Modality Associations.

Authors:  Tamar Phirtskhalaishvili; Florian Bayer; Stephane Edet; Isabelle Bongiovanni; Julien Hogan; Cécile Couchoud
Journal:  Perit Dial Int       Date:  2015-10-16       Impact factor: 1.756

8.  Geographic and temporal trends in peritoneal dialysis services in the United States between 1995 and 2003.

Authors:  Virginia Wang; Shoou-Yih D Lee; Uptal D Patel; Bryan J Weiner; Thomas C Ricketts; Morris Weinberger
Journal:  Am J Kidney Dis       Date:  2010-04-10       Impact factor: 8.860

9.  Comparison of direct medical costs between automated and continuous ambulatory peritoneal dialysis.

Authors:  Laura Cortés-Sanabria; Brenda E Rodríguez-Arreola; Victor R Ortiz-Juárez; Herman Soto-Molina; Leonardo Pazarín-Villaseñor; Héctor R Martínez-Ramírez; Alfonso M Cueto-Manzano
Journal:  Perit Dial Int       Date:  2013-04-01       Impact factor: 1.756

Review 10.  Peritoneal dialysis--current status and future challenges.

Authors:  Simon J Davies
Journal:  Nat Rev Nephrol       Date:  2013-05-21       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.